AAPS PharmSciTech

, Volume 18, Issue 4, pp 1288–1292 | Cite as

Development and Optimization of an Ex Vivo Colloidal Stability Model for Nanoformulations

  • Muhammad Vaseem Shaikh
  • Manika Kala
  • Manish Nivsarkar
Rapid Communication

Abstract

Nanotechnology is having a significant impact in the drug delivery systems and diagnostic devices. As most of the nanosystems are intended to be administered in vivo, there is a need for stability models, which could simulate the biological environment. Instability issues could lead to particle aggregation and in turn could affect the release of the drug from the nanosystems and even lead to clogging of the systemic blood circulation leading to life-threatening situation. We have developed an ex vivo colloidal stability model for testing the stability of nanosystems over a period of 48 h, which is the typical residence time of the nanoparticles in vivo. Tissue homogenates of rat spleen, brain, kidney, and liver were stabilized and optimized for the study; additionally, plasma and serum were used for the same. Poly (lactide-co-glycolic acid) nanoparticles were used as model nanosystem, and no significant change was found in the size and polydispersity index of the nanoparticles in the biological solutions. Moreover, no change in morphology was observed after 48 h as observed by TEM microscopy. Hence, the developed model could prevent the failure of the developed nanosystem during clinical and preclinical application by serving as an initial checkpoint to study their interaction with the complex milieu.

Keywords

ex vivo colloidal stability PLGA nanoparticle nanosystem 

Supplementary material

12249_2016_597_MOESM1_ESM.docx (12 kb)
Supplementary Table 1PDI of PLGA-NPs in different tissue homogenates. Data expressed as mean ± SD (n = 3) (DOCX 11 kb)
12249_2016_597_MOESM2_ESM.docx (11 kb)
Supplementary Table 2Zeta potential of PLGA-NPs in different tissue homogenates. No significant difference was observed in zeta potential of NPs measured at different time points in tissue homogenates. Data expressed as mean ± SD (n = 3). (DOCX 11 kb)
12249_2016_597_Fig6_ESM.gif (9 kb)
Supplementary Fig. 1

Colloidal stability of PLGA-NPs in PBS at 37°C. (GIF 8 kb)

12249_2016_597_MOESM3_ESM.tif (358 kb)
High resolution image (TIF 357 kb)

References

  1. 1.
    Kayser O, Lemke A, Hernandez-Trejo N. The impact of nanobiotechnology on the development of new drug delivery systems. Curr Pharm Biotech. 2005;6(1):3–5.CrossRefGoogle Scholar
  2. 2.
    Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomed Nanotech Biol Med. 2012;8(2):147–66.Google Scholar
  3. 3.
    Weissig V, Pettinger TK, Murdock N. Nanopharmaceuticals (part I): products on the market. Int J Nanomed. 2014;9:4357–73.CrossRefGoogle Scholar
  4. 4.
    De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomed. 2008;3(2):133–49.CrossRefGoogle Scholar
  5. 5.
    Alkilany AM, Murphy CJ. Toxicity and cellular uptake of gold nanoparticles: what we have learned so far. J Nanopart Res. 2010;12(7):2313–33.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Cedervall T, Lynch I, Lindman S, Berggård T, Thulin E, Nilsson H, et al. Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. ProcNatlAcadSci USA. 2007;104(7):2050–55.CrossRefGoogle Scholar
  7. 7.
    Radomski A, Jurasz P, Alonso‐Escolano D, Drews M, Morandi M, Malinski T, et al. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol. 2005;146(6):882–93.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Sayes CM, Gobin AM, Ausman KD, Mendez J, West JL, Colvin VL. Nano-C60 cytotoxicity is due to lipid peroxidation. Biomater. 2005;26(36):7587–95.CrossRefGoogle Scholar
  9. 9.
    SCENIHR (Scientific Committee on Emerging and Newly-Identified Health Risks), The appropriateness of the risk assessment methodology in accordance with the Technical Guidance Documents for new and existing substances for assessing the risks of nanomaterials; 2007.Google Scholar
  10. 10.
    Tewes F, Munnier E, Antoon B, Okassa LN, Cohen-Jonathan S, Marchais H, et al. Comparative study of doxorubicin-loaded poly (lactide-co-glycolide) nanoparticles prepared by single and double emulsion methods. Eur J Pharm Biopharm. 2007;66(3):488–92.CrossRefPubMedGoogle Scholar
  11. 11.
    Rizzardini M, Zappone M, Villa P, Gnocchi P, Sironi M, Diomede L, et al. Kupffer cell depletion partially prevents hepatic hemeoxygenase 1 messenger RNA accumulation in systemic inflammation in mice: role of interleukin 1beta. Hepatol. 1998;27(3):703–10.CrossRefGoogle Scholar
  12. 12.
    Dar AM, Naseem S, Gatoo MA, Arfat MY, Qasim K. In vivo toxicity of nanoparticles: modalities and treatment. Euro Chem Bullet. 2014;3(10–12):992–00.Google Scholar
  13. 13.
    He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomater. 2010;31(13):3657–66.CrossRefGoogle Scholar
  14. 14.
    Lazzari S, Moscatelli D, Codari F, Salmona M, Morbidelli M, Diomede L. Colloidal stability of polymeric nanoparticles in biological fluids. J Nanopart Res. 2013;14(6):1–10.Google Scholar
  15. 15.
    Friedler A, Veprintsev DB, Hansson LO, Fersht AR. Kinetic instability of p53 core domain mutants: implications for rescue by small molecules. J Biol Chem. 2003;278(26):24108–12.CrossRefPubMedGoogle Scholar
  16. 16.
    Plaza del Pino IM, Ibarra‐Molero B, Sanchez‐Ruiz JM. Lower kinetic limit to protein thermal stability: a proposal regarding protein stability in vivo and its relation with misfolding diseases. Proteins StructFunctBioinform. 2000;40(1):58–70.CrossRefGoogle Scholar
  17. 17.
    Hughes AB. Amino acids, peptides and proteins in organic chemistry, Chapter: analysis and function of amino acids and peptides (Amino acids, peptides and proteins in organic chemistry (VCH)). Wiley. 2013;5:298–99.Google Scholar
  18. 18.
    Kim J, Lee H, Shin S. Advances in the measurement of red blood cell deformability: a brief review. J Cell Biotech. 2015;1(1):63–79.CrossRefGoogle Scholar
  19. 19.
    Kragh-Hansen U. Structure and ligand binding properties of human serum albumin. Dan Med Bull. 1990;37(1):57–84.PubMedGoogle Scholar
  20. 20.
    Marini I, Moschini R, Del Corso A, Mura U. Chaperone-like features of bovine serum albumin. A comparison with α-crystallin. Cell Mol Life Sci. 2005;62(24):3092–99.CrossRefPubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2016

Authors and Affiliations

  • Muhammad Vaseem Shaikh
    • 1
    • 2
  • Manika Kala
    • 1
    • 2
  • Manish Nivsarkar
    • 1
  1. 1.Department of Pharmacology and ToxicologyB. V. Patel Pharmaceutical Education and Research Development (PERD) CentreAhmedabadIndia
  2. 2.Faculty of PharmacyNIRMA UniversityAhmedabadIndia

Personalised recommendations